We are live on
!
Find out more
IC
Ikarian Capital Portfolio holdings
AUM
$1.23B
1-Year Est. Return
600.17%
This Fund
S&P 500
This Quarter
Est. Return
+39.15%
1 Year Est. Return
+600.17%
3 Year Est. Return
+5,763.15%
5 Year Est. Return
+15,527.6%
10 Year Est. Return
–
AUM
$831M
AUM Growth
+$203M
(+32%)
Cap. Flow
-$333M
Cap. Flow
% of AUM
-40.1%
Top 10 Holdings %
Top 10 Hldgs %
41.06%
Holding
181
New
59
Increased
25
Reduced
46
Closed
41
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Rocket Pharmaceuticals
RCKT
|
+$11.9M |
| 2 |
AKRO
Akero Therapeutics
AKRO
|
+$9.31M |
| 3 |
Tarsus Pharmaceuticals
TARS
|
+$9.18M |
| 4 |
CPRX
Catalyst Pharmaceutical
CPRX
|
+$6.77M |
| 5 |
Immunovant
IMVT
|
+$6.73M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Merck
MRK
|
+$11.5M |
| 2 |
Insmed
INSM
|
+$7.55M |
| 3 |
IDEAYA Biosciences
IDYA
|
+$6.95M |
| 4 |
Biohaven
BHVN
|
+$6.68M |
| 5 |
Biomea Fusion
BMEA
|
+$6.06M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 31.68% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
PUT
CRISPR Therapeutics
CRSP
$4.77B
| $9.26M | 1.11% |
2,039
-197,961
| -99% | -$10.2M |
|
|
27
Tarsus Pharmaceuticals
TARS
$2.6B
| $9.21M | 1.11% |
+518,519
| New | +$9.18M |
|
28
PUT
BioMarin Pharmaceuticals
BMRN
$11.7B
| $9.01M | 1.08% |
1,018
-98,982
| -99% | -$8.81M |
|
|
APLS
29
CALL
DELISTED
Apellis Pharmaceuticals
APLS
| $9M | 1.08% |
+2,365
| New | +$104K |
|
30
PUT
Novavax
NVAX
$1.22B
| $8.78M | 1.06% |
12,132
-387,868
| -97% | -$3.1M |
|
31
CALL
BridgeBio Pharma
BBIO
$16.1B
| $8.05M | 0.97% |
3,054
-1,226,746
| -100% | -$34.8M |
|
32
Vaxcyte
PCVX
$8.08B
| $7.26M | 0.87% |
142,417
+2,417
| +2% | +$119K |
|
33
CALL
Arcus Biosciences
RCUS
$3.55B
| $7.18M | 0.86% |
4,000
-196,000
| -98% | -$3.94M |
|
34
PUT
Disc Medicine
IRON
$3.03B
| $7.17M | 0.86% |
+1,526
| New | +$76.3K |
|
35
Structure Therapeutics
GPCR
$3.52B
| $6.95M | 0.84% |
+137,824
| New | +$4.44M |
|
|
36
Disc Medicine
IRON
$3.03B
| $6.71M | 0.81% |
142,766
-97,265
| -41% | -$4.87M |
|
37
Ultragenyx Pharmaceutical
RARE
$2.56B
| $6.24M | 0.75% |
174,945
+53,287
| +44% | +$2.11M |
|
|
IMGN
38
DELISTED
Immunogen Inc
IMGN
| $6.19M | 0.74% |
390,162
-57,538
| -13% | -$957K |
|
|
MRNS
39
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
| $6.01M | 0.72% |
746,069
+134,137
| +22% | +$1.12M |
|
40
CALL
Cytokinetics
CYTK
$10.9B
| $6M | 0.72% |
+2,035
| New | +$67.8K |
|
|
41
PUT
Cytokinetics
CYTK
$10.9B
| $6M | 0.72% |
+2,035
| New | +$67.8K |
|
|
CPRX
42
DELISTED
Catalyst Pharmaceutical
CPRX
| $5.91M | 0.71% |
+505,862
| New | +$6.77M |
|
|
43
IDEAYA Biosciences
IDYA
$3.5B
| $5.85M | 0.7% |
216,949
-273,944
| -56% | -$6.95M |
|
|
AMAM
44
CALL
DELISTED
Ambrx Biopharma Inc
AMAM
| $5.67M | 0.68% |
+4,932
| New | +$67.2K |
|
|
IMGN
45
CALL
DELISTED
Immunogen Inc
IMGN
| $5.66M | 0.68% |
3,568
-346,432
| -99% | -$5.76M |
|
46
PUT
Revolution Medicines
RVMD
$40.9B
| $5.63M | 0.68% |
+2,035
| New | +$60.4K |
|
47
CALL
Jazz Pharmaceuticals
JAZZ
$16.2B
| $5.41M | 0.65% |
+418
| New | +$55.7K |
|
|
ETNB
48
CALL
DELISTED
89bio
ETNB
| $5.41M | 0.65% |
+3,504
| New | +$58.8K |
|
|
49
CALL
Novavax
NVAX
$1.22B
| $5.16M | 0.62% |
7,132
-392,868
| -98% | -$3.14M |
|
|
LYRA
50
DELISTED
LYRA THERAPEUTICS INC
LYRA
| $4.9M | 0.59% |
25,088
+5,515
| +28% | +$987K |
|
Similar funds
FLII
NHAS
HCA
GX
WCM
MP
IA
IB
Ikarian Capital's Q3 2023 Portfolio in Review
As of Q3 2023, Ikarian Capital held 181 positions worth $831M, up 32% from $628M the previous quarter. Its ten largest holdings account for 41% of the portfolio.
Ikarian Capital withdrew a net $333M in Q3 2023, closing 41 positions and reducing 46 holdings. Its most notable exit was Merck, an estimated $11.5M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 32% of assets, down from 44% a quarter earlier.
Against the trend, Ikarian Capital opened a new position in Rocket Pharmaceuticals worth $13.4M.
- Ikarian Capital's largest Q3 2023 buy was Rocket Pharmaceuticals: 654,726 shares worth $13.4M.
- Ikarian Capital added most to Crinetics Pharmaceuticals in Q3 2023, an estimated $6.55M increase.
- Ikarian Capital's biggest Q3 2023 reduction was Insmed, cutting an estimated $7.55M.
- Ikarian Capital fully exited Merck in Q3 2023, selling an estimated $11.5M.
- Ikarian Capital's ten largest holdings make up 41% of its $831M portfolio in Q3 2023.
- Ikarian Capital opened 59 new positions and closed 41 in Q3 2023.
- Ikarian Capital's portfolio value rose 32% quarter-over-quarter to $831M.
Based on Ikarian Capital's 13F filing for Q3 2023, filed 14 Nov 2023.